Results of using Pembrolizumab and Nivolumab, immune checkpoint inhibitors (ICIs), in third-line therapy for patients with metastatic gastric cancer. Experience of Moscow oncology service
https://doi.org/10.21294/1814-4861-2025-24-3-93-102
Abstract
Background. There is limited data on the effectiveness of immune checkpoint inhibitors (ICIs) in third-line therapy for metastatic gastric cancer.
The aim of the study was to compare progression-free survival (PFS) and overall survival (OS) in patients with metastatic gastric cancer receiving third-line immunotherapy or chemotherapy.
Material and Methods. In third-line treatment for metastatic gastric cancer, the long-term outcomes (PFS and OS) of ICI (n=93) or chemotherapy (n=77) were retrospectively evaluated. The study group comprised 170 patients; 63.4 % were males and 53.2 % were females. The median age was 65.5 and 63.7 years in ICN and chemotherapy groups, respectively. ECOG 2 was 22.6 % and 16.9 %, respectively. The ICI group had worse PFS in second-line therapy (2.8 and 4.8 months, p=0.0014), and fewer patients continued treatment after progression (14 % and 39 %, p=0.002). In the chemotherapy group, 80 % of patients received ICIs in fourthand later lines of treatment.
Results. The analysis showed that PFS was better in the chemotherapy group than in the ICI group (4.3 vs 2.4 months, p=0.12, HR 1.28, 95 % CI 0.94–1.76), OS was also better in the chemotherapy group than in the ICI group (7.8 vs 4.8 months, p=0.064, HR 1.35, 95 %CI 0.98–1.85). The influence of the CPS level (0–9/unknown and ≥10) in the ICI group was not found: PFS 2.1 and 2.4 months (p=0.75), OS 4.1 and 4.4 months (p=0.62). When comparing PFS and OS in patients with MSI/dMMR who received ICI (n=6) and chemotherapy (n=5), no benefits of using ICT was shown (PFS 3.4 and 9.7 months, p=0.75, and OS 11.9 and 13.0 months, p=0.56). During the first follow-up, disease stabilization was observed in 26 % and 44.2 % of patients, respectively (p=0.015 %).
Conclusion. The use of ICT in third-line treatment for metastatic gastric cancer was inferior to standard treatment regimens in terms of PFS and OS (regardless of CPS level and presence of MSI). Given the risks of rapid progression in ICI-treated patients, the presence of a small subgroup of patients (no more than 10 %) who benefit from classical treatment approaches with long follow-up periods, it is necessary to continue the search for factors associated with the effectiveness of ICI.
About the Authors
N. N. Semenov
A.S. Loginov Moscow Medical Scientific Center, Moscow City Health Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Nikolay N. Semenov - MD, DSc, Leading Researcher, Chemotherapy Department, A.S. Loginov Moscow Medical Scientific Center, Moscow City Health Department; Leading Researcher, Abdominal Oncology Department, N.I. Pirogov RNRMU, Ministry of Health of Russia.
1, Novogireevskaya St., Moscow, 117513; 6, Ostrovityanova St., Moscow, 117513
M. Y. Fedyanin
City Budgetary Hospital “MMCC “Kommunarka”, Moscow City Health Department; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov National Medical and Surgical Center, Ministry of Health of Russia
Russian Federation
Russian Federation
Mikhail Y. Fedyanin - MD, DSc, Head of Chemotherapy Treatment Service, City Budgetary Hospital “MMCC “Kommunarka”, Moscow City Health Department; Head of Science Department, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Head of Oncology Department, Institute of Postgraduate Education, N.I. Pirogov National Medical and Surgical Center, Ministry of Health of Russia.
8, Sosenskiy stan St., Sosenskoye settlement, Kommunarka village, Moscow, 108814; 24, Kashirskoe shosse, Moscow, 115522; 70, Nizhnyaya Pervomayskaya St., Moscow, 105203
L. G. Zhukova
A.S. Loginov Moscow Medical Scientific Center, Moscow City Health Department
Russian Federation
Russian Federation
Lyudmila G. Zhukova - MD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Deputy Director for Oncology, A.S. Loginov Moscow Medical Scientific Center.
1, Novogireevskaya St., Moscow, 117513
I. E. Khatkov
A.S. Loginov Moscow Medical Scientific Center, Moscow City Health Department; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Russian Federation
Igor E. Khatkov - MD, DSc, Professor, Academician of the Russian Academy of Sciences, Director, A.S. Loginov Moscow Medical Scientific Center, Moscow City Health Department; Head of the Department of Faculty Surgery No. 2, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia.
1, Novogireevskaya St., Moscow, 117513; 4, Dolgorukovskaya St., Moscow, 127006
D. L. Stroyakovsky
City Clinical Oncology Hospital № 62, Moscow City Health Department
Russian Federation
Russian Federation
Daniil L. Stroyakovsky - MD, PhD, Head of the Chemotherapy Department, City Clinical Oncology Hospital № 62.
27, Istra village, Krasnogorsk city district, Moscow region, 143515
I. A. Pokataev
S.S. Yudin City Clinical Hospital, Moscow City Health Department
Russian Federation
Russian Federation
Ilya A. Pokataev - MD, DSc, Head of the Chemotherapy Treatment Service, S.S. Yudin City Clinical Hospital.
18A, Zagorodnoye shosse, Moscow, 117152
References
1. Shin S.J., Jeung H.C., Ahn J.B., Choi H.J., Cho B.C., Rha S.Y., Yoo N.C., Roh J.K., Chung H.C. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer Chemother Pharmacol. 2008; 61(1): 157–65. doi: 10.1007/s00280-007-0470-3.
2. Lee J.H., Kim S.H., Oh S.Y., Lee S., Lee H., Lee H.J., Kim H.J. Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer. Korean J Intern Med. 2013; 28(3): 314–21. doi: 10.3904/kjim.2013.28.3.314.
3. Kang J.H., Lee S.I., Lim D.H., Park K.W., Oh S.Y., Kwon H.C., Hwang I.G., Lee S.C., Nam E., Shin D.B., Lee J., Park J.O., Park Y.S., Lim H.Y., Kang W.K., Park S.H. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012; 30(13): 1513–18. doi: 10.1200/JCO.2011.39.4585. Erratum in: J Clin Oncol. 2012; 30(24): 3035.
4. Kang E.J., Im S.A., Oh D.Y., Han S.W., Kim J.S., Choi I.S., Kim J.W., Kim Y.J., Kim J.H., Kim T.Y., Lee J.S., Bang Y.J., Lee K.W. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. Gastric Cancer. 2013; 16(4): 581–89. doi: 10.1007/s10120-012-0227-5.
5. Kawakami T., Machida N., Yasui H., Kawahira M., Kawai S., Kito Y., Yoshida Y., Hamauchi S., Tsushima T., Todaka A., Yokota T., Yamazaki K., Fukutomi A., Onozawa Y. Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer. Cancer Chemother Pharmacol. 2016; 78(4): 809–14. doi: 10.1007/s00280-016-3138-z.
6. Pasquini G., Vasile E., Caparello C., Vivaldi C., Musettini G., Lencioni M., Petrini I., Fornaro L., Falcone A. Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. Oncology. 2016; 91(6): 311–16. doi: 10.1159/000443962.
7. Yamaguchi K., Nakagawa S., Yabusaki H., Nashimoto A. Combination chemotherapy with 5-fluorouracil, cisplatin and paclitaxel for pretreated patients with advanced gastric cancer. Anticancer Res. 2007; 27(5B): 3535–39.
8. Fushida S., Kinoshita J., Kaji M., Oyama K., Hirono Y., Tsukada T., Fujimura T., Ohta T. Paclitaxel plus valproic acid versus paclitaxel alone as secondor third-line therapy for advanced gastric cancer: a randomized Phase II trial. Drug Des Devel Ther. 2016; 10: 2353–58. doi: 10.2147/DDDT.S110425.
9. Moehler M., Gepfner-Tuma I., Maderer A., Thuss-Patience P.C., Ruessel J., Hegewisch-Becker S., Wilke H., Al-Batran S.E., Rafiyan M.R., Weißinger F., Schmoll H.J., Kullmann F., von Weikersthal L.F., Siveke J.T., Weusmann J., Kanzler S., Schimanski C.C., Otte M., Schollenberger L., Koenig J., Galle P.R. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer. 2016; 16(1): 699. doi: 10.1186/s12885-016-2736-9.
10. Shitara K., Doi T., Dvorkin M., Mansoor W., Arkenau H.T., Prokharau A., Alsina M., Ghidini M., Faustino C., Gorbunova V., Zhavrid E., Nishikawa K., Hosokawa A., Yalçın Ş., Fujitani K., Beretta G.D., Cutsem E.V., Winkler R.E., Makris L., Ilson D.H., Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018; 19(11): 1437–48. doi: 10.1016/S1470-2045(18)30739-3. Erratum in: Lancet Oncol. 2018; 19(12): e668. doi: 10.1016/s1470-2045(18)30843-X.
11. Pavlakis N., Sjoquist K.M., Martin A.J., Tsobanis E., Yip S., Kang Y.K., Bang Y.J., Alcindor T., O’Callaghan C.J., Burnell M.J., Tebbutt N.C., Rha S.Y., Lee J., Cho J.Y., Lipton L.R., Wong M., Strickland A., Kim J.W., Zalcberg J.R., Simes J., Goldstein D. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational PlaceboControlled Phase II Trial. J Clin Oncol. 2016; 34(23): 2728–35. doi: 10.1200/JCO.2015.65.1901.
12. Pavlakis N., Shitara K., Sjoquist K., Martin A., Jaworski A., Tebbutt N., Bang Y.J., Alcindor T., O’Callaghan C., Strickland A., Rha S.Y., Lee K.W., Kim J.S., Bai L.Y., Hara H., Oh D.Y., Yip S., Zalcberg J., Price T., Simes J., Goldstein D. INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer. J Clin Oncol. 2025; 43(4): 453–63. doi: 10.1200/JCO.24.00055.
13. Kang Y.K., Boku N., Satoh T., Ryu M.H., Chao Y., Kato K., Chung H.C., Chen J.S., Muro K., Kang W.K., Yeh K.H., Yoshikawa T., Oh S.C., Bai L.Y., Tamura T., Lee K.W., Hamamoto Y., Kim J.G., Chin K., Oh D.Y., Minashi K., Cho J.Y., Tsuda M., Chen L.T. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-453812, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10111): 2461–71. doi: 10.1016/S01406736(17)31827-5.
14. Gastric cancer: сlinical recommendations of the Ministry of Health of the Russian Federation. 2020. (in Russian)]. [Internet]. [cited 11.04.2025]. URL: https://cr.minzdrav.gov.ru/previewcr/574_1.
15. Besova N.S., Bolotina L.V., Gamayunov S.V., Kalinin A.E., Kozlov N.A., Malikhova O.A., Nered S.N., Pirogov S.S., Protsenko S.A., Stilidi I.S., Teletaeva G.M., Ter-Ovanesov M.D., Tryakin A.A., Khomyakov V.M., Chernykh M.V. Gastric cancer. Practical recommendations RUSSCO, part 1.1. Malignant Tumors. 2024; 14(3s2): 241–62. (in Russian). EDN: RXJTCA.
16. Shim H.J., Yun J.Y., Hwang J.E., Bae W.K., Cho S.H., Chung I.J. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer. 2011; 14(3): 249–56. doi: 10.1007/s10120-011-0032-6.
17. Kanagavel D., Pokataev I.A., Fedyanin M.Y., Tryakin A.A., Bazin I.S., Narimanov M.N., Yakovleva E.S., Garin A.M., Tjulandin S.A. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol. 2010; 21(9): 1779–85. doi: 10.1093/annonc/mdq032.
Review
For citations:
Semenov N.N., Fedyanin M.Y., Zhukova L.G., Khatkov I.E., Stroyakovsky D.L., Pokataev I.A. Results of using Pembrolizumab and Nivolumab, immune checkpoint inhibitors (ICIs), in third-line therapy for patients with metastatic gastric cancer. Experience of Moscow oncology service. Siberian journal of oncology. 2025;24(3):93-102. (In Russ.) https://doi.org/10.21294/1814-4861-2025-24-3-93-102
Views:
50
Email this article 
